Hematology · Pediatrics · Infectious Disease · 3 h ago
CMV-Positive Pediatric ITP Linked to Greater Early Treatment Needs, Higher 12-Month Remission
A single-center retrospective cohort of 444 children with immune thrombocytopenia included 25 who were CMV-positive. These children more often required multiple initial treatment courses but had higher 12-month remission rates than CMV-negative children, despite similar bleeding severity at diagnosis.
- CMV positivity occurred in 5.6% of children with ITP.
- CMV-positive children required more initial treatment despite similar bleeding severity.
- Twelve-month remission was 84% versus 59.6% in CMV-negative children.
- Retrospective design and small CMV-positive subgroup limit certainty.
A single-center retrospective cohort study in Pediatric Blood & Cancer examined whether cytomegalovirus (CMV) status was associated with the clinical course of pediatric immune thrombocytopenia (ITP). Investigators compared presentation, treatment requirements, and outcomes among 444 children, including 25 (5.6%) who were CMV-positive, and used logistic regression to assess associations with remission.
At diagnosis, CMV-positive children had lower median platelet counts than CMV-negative children (5,000 versus 11,000/µL; p = 0.01), lower hemoglobin and absolute neutrophil counts, and more frequent transaminase elevation. Bleeding severity was similar. Multiple initial treatment courses were more common in CMV-positive patients (52.2% versus 17.8%; p < 0.001). However, between 3 and 12 months, fewer received treatment (8% versus 30.6%; p = 0.01), and 12-month remission was more frequent (84% versus 59.6%; p = 0.018). Only one CMV-positive patient received antiviral therapy.
CMV positivity remained associated with 12-month remission in multivariable analysis (odds ratio 3.78; 95% CI 1.0004–20.16). These findings suggest CMV status may provide prognostic information despite greater early treatment requirements. However, the retrospective, single-center design, small CMV-positive subgroup, and wide confidence interval limit certainty and generalizability. The abstract does not establish a benefit from routine CMV testing or antiviral treatment; full text was unavailable for review.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Pediatric Blood & Cancer: Biphasic Clinical Course of Pediatric Cytomegalovirus‐Associated Immune Thrombocytopenia: Early Poor Treatment Response but Favorable Long‐Term Outcomes ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.